Sifalimumab (MEDI-545), a fully humanized IgG1 monoclonal antibody against IFNα, exhibited good tolerability and inhibited the type I IFN signature in some patients with SLE [72,73]. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.